Spring Bio Solution: Spring Bio Solution, a global leader in comparator sourcing and clinical trial supplies, has launched NCE Grid, touted as the world's first free new chemical entity (NCE-1) intelligence platform - built to decode, centralise, and visualise Paragraph IV (Para IV) opportunities in real-time. According to BERNAMA News Agency, the company stated that the platform addresses long-standing challenges in the pharmaceutical industry, where tracking NCE exclusivity expirations and Para IV filings has been a fragmented and manual process, often relying on spreadsheets and siloed databases. Spring Bio Solution Founder and Chief Executive Officer, Salim Shaikh, expressed that NCE Grid was developed to tackle the issue of fragmented insights and missed opportunities faced by many companies. He highlighted the significance of timing in the industry, stating, "Our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid - your trusted guide for s trategic drug development." NCE Grid consolidates key data points, including molecule, innovator name, NCE-1 date, revenue, therapeutic applications, sales forecasts, and percentage of compound annual growth rates (CAGR), into one intuitive platform. The platform is designed to support regulatory, strategy, and portfolio teams by providing real-time insights that help identify and prioritize first-to-file opportunities, a crucial factor for generic pharmaceutical companies competing for market exclusivity.